Di Meco et al. (2017) reported that the enzymatic activity of 12/15-lipoxygenase (12/15-LOX) was significantly increased in the brains of AD patients, and its protein levels influence the memory and learning abilities in mouse model. Importantly, pharmacological inhibition of 12/15-LOX can reverse this AD-like phenotype (Di Meco et al., 2017). This evidence concerns the gene SPRR2A and Alzheimer disease.